Tuesday, November 10, 2009

Microbix Receives Approval To Market Thrombolytic Agent Kinlytic (urokinase) In Canada

Nov. 10 -- Microbix Biosystems Inc. (MBX:TSX) today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.

The details can be read here.

No comments: